A new approach to percutaneous transhepatic portal embolization using ethanolamine oleate iopamidol.
OBJECTIVE
We aimed to examine the therapeutic efficacy of ethanolamine oleate iopamidol (EOI) as an embolic material for percutaneous transhepatic portal embolization (PTPE).


METHODS
Eighty-two patients with liver tumors were treated with PTPE. Fifty-eight patients had hepatocellular carcinomas, 11 had liver metastases, and 13 had other liver tumors. A total of 55 patients (group E) were treated with 5% ethanolamine oleate after gelatin sponge administration. As a control, we evaluated 27 patients (group F) who were treated with fibrin glue and iodized oil. PTPE was mainly indicated before hepatic resection, for patients with high nontumorous volumetric resection ratios (the nontumorous volumetric resection ratio was estimated to be greater than 65% in patients with an indocyanine green retention ratio of 15 min (ICG R15) of 10% or less, and the nontumorous volumetric resection ratio was estimated to be greater than 40% in the patients with an ICG R15 of 10-20%).


RESULTS
All patients were successfully treated percutaneously under local anesthesia. Balloon-occluded and ipsilateral approaches were used in 81 patients (99%) and 62 (75%) patients, respectively. The rate of insufficient embolization or recanalization was significantly lower in group E (7.3%) in comparison to group F (25.9%; p < 0.05). The volumetric resection ratios, before and after PTPE, decreased from 60 to 45% in group E and from 63 to 55% in group F. The post-PTPE resection ratio was significantly decreased in group E. Before and after PTPE, average ICG R15 values changed from 17 to 27% in group E and from 18 to 26% in group F. The complication rates in groups E and F were similar (7.3 vs. 7.4%).


CONCLUSIONS
EOI is a safe embolic material that can be used to induce greater liver hypertrophy, in comparison to fibrin glue, in PTPE for liver tumors.
Beppu
Toru
T
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto 860-8556, Japan. tbeppu@kumamoto-u.ac.jp
Iwatsuki
Masaaki
M
Okabe
Hirohisa
H
Okabe
Kazutoshi
K
Masuda
Toshiro
T
Hayashi
Hiromitsu
H
Sugiyama
Shinichi
S
Horino
Kei
K
Komori
Hiroyuki
H
Hayashi
Naoko
N
Takamori
Hiroshi
H
Ishiko
Takatoshi
T
Baba
Hideo
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D021721:Balloon Occlusion / Q000379:methods; D006528:Carcinoma, Hepatocellular / Q000628:therapy; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D005260:Female; D015718:Fibrin Tissue Adhesive / Q000008:administration & dosage; D005781:Gelatin Sponge, Absorbable / Q000008:administration & dosage; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D007479:Iopamidol / Q000008:administration & dosage* / Q000009:adverse effects; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009829:Oleic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000009:adverse effects
D015718:Fibrin Tissue Adhesive; D009829:Oleic Acids; D012597:Sclerosing Solutions; D007459:Iodized Oil; D007479:Iopamidol; C033343:ethanolamine oleate